Priority Review for Roche's MS candidate

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA accepted and granted Priority Review to a BLA for Ocrevus ocrelizumab to treat the relapsing and primary progressive forms of multiple sclerosis. Its PDUFA date is Dec. 28.

Last October, Roche announced data from two Phase III studies of Ocrevus to treat relapsing MS and one Phase III study in primary progressive MS (see BioCentury Extra, Oct. 8). ...